AZ 002 - Azymus Therapeutics
Alternative Names: AZ-002 - Azymus TherapeuticsLatest Information Update: 28 Feb 2024
At a glance
- Originator Azymus Therapeutics
- Class Antineoplastics; Exosome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 21 Jan 2020 Early research in Cancer in USA (Parenteral) before January 2020
- 16 Jan 2020 AZ 002 - Azymus Therapeutics is available for licensing as of 30 Jan 2020. https://azymustherapeutics.com/